- Innate Pharma (IPHA, Financial) regains rights for CD123 targeting ANKET® - SAR’579/IPH6101.
- Sanofi intends to invest up to €15 million in Innate Pharma.
- Sanofi to shift BCMA targeting ANKET® program toward autoimmune indications.
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) has announced the reacquisition of its rights to the CD123 targeting ANKET® technology, specifically SAR’579/IPH6101. This decision follows a mutual agreement with Sanofi to terminate parts of their 2016 Research Collaboration and License Agreement.
Sanofi has expressed its intent to invest up to €15 million in Innate Pharma through a capital increase. The details regarding the size and pricing of this investment will be contingent upon current market conditions.
Continuing to align with strategic priorities, Sanofi plans to redirect its BCMA targeting ANKET® program, SAR’514/IPH6401, from multiple myeloma to autoimmune indications. The original clinical study for treatment of relapsed or refractory multiple myeloma associated with SAR’514/IPH6401 will be concluded prematurely.
Innate Pharma remains eligible for over €1 billion in research & development and commercial milestone payments related to their ongoing agreements with Sanofi. The Phase 1/2 study of SAR’579/IPH6101 for relapsed or refractory acute myeloid leukemia (AML) has demonstrated clinical benefits, with five complete responses at a dosage of 1 mg/kg.
Innate Pharma continues to focus on innovative immunotherapy development for cancer patients, aiming to harness the body's innate immune system through their proprietary ANKET® platform. The company maintains a strategic partnership with biopharmaceutical leaders like Sanofi and AstraZeneca.
